Article Text

AB0432 ABT-494 has no effect on the QT interval at the doses being evaluated in rheumatoid arthritis phase 3 trials
  1. M-EF Mohamed,
  2. J Zeng,
  3. P Jiang,
  4. B Hosmane,
  5. AA Othman
  1. Clinical Pharmacology and Pharmacometrics, AbbVie, North Chicago, United States


Background ABT-494 is a selective Janus Kinase 1 inhibitor currently being evaluated in Phase 3 trials for treatment of rheumatoid arthritis (RA) at doses of 15 mg and 30 mg once daily using the extended-release tablet formulation. Exposure-response analysis of ECG data collected at early stage clinical trials has been recently adopted in regulatory guidelines as a tool to assess the proarrhythmic risk of investigational new drugs.

Objectives The objective of this work was to evaluate ABT-494 QT prolongation potential using exposure-response analysis of data collected in early Phase 1 studies.

Methods Doses of ABT-494 or placebo were administered to healthy subjects in two Phase 1 studies. Evaluated ABT-494 immediate-release regimens ranged from 1 mg to 48 mg single doses under fasting conditions and 3 mg to 24 mg twice daily under non-fasting conditions. Serial triplicate electrocardiograms and pharmacokinetic assessments were conducted. The relationship between change from baseline in Fridericia-corrected QT interval (QTcF) and ABT-494 plasma concentrations was characterized using linear mixed-effects modeling. To evaluate the ECG assay sensitivity, the change in QTcF from baseline to 2 hours post-dose was compared for subjects who received placebo under fasting and non-fasting conditions.

Results There was no statistically significant relationship between the change from baseline in the QTcF interval and ABT-494 plasma concentrations. The point estimate of the effect on QTcF for the highest concentration observed in the evaluated studies, which is approximately 4-fold higher than the mean Cmax of the highest RA Phase 3 dose, is –1.77 msec (with upper bound of the 95% one-sided confidence interval of 3.33 msec; lower than the regulatory threshold of concern of 10 msec). Food shortened the QTcF interval by 5.9 msec (2-sided 90% confidence interval of -9.6 to -2.1 msec), indicating that the ECG assay used in the studies had adequate sensitivity to detect the small change in QTcF caused by food.

Conclusions ABT-494 showed no potential for QT prolongation at the expected therapeutic and supra-therapeutic plasma exposures for the doses being used in Phase 3 RA trials.

Disclosure of Interest M.-E. Mohamed Shareholder of: AbbVie, Employee of: AbbVie, J. Zeng Shareholder of: AbbVie, Employee of: AbbVie, P. Jiang Shareholder of: AbbVie, Employee of: AbbVie, B. Hosmane Shareholder of: AbbVie, Employee of: AbbVie, A. Othman Shareholder of: AbbVie, Employee of: AbbVie

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.